AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16554525
Drug: Sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg
Trial: 16554525
Drug: Sertraline (238
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (238 patients) at a maximal daily dose of 200 mg
Trial: 16554525
Drug: Extended-release venlafaxine
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg
Trial: 16554526
Drug: Sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion (up to 400 mg per day)
Trial: 16554526
Drug: Buspirone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (up to 60 mg per day)
Trial: 16554527
Drug: ACAT inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACAT inhibitor pactimibe (100 mg per day)
Trial: 16563165
Drug: Weekly pediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly pediatric evaluation and referral to appropriate care for infants with cleft lip and/or palate.
Trial: 16628299
Drug: Parenteral penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral penicillin or oral amoxicillin (WHO standard treatment)
Trial: 16681848
Drug: Cetuximab (Erbitux)
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab (Erbitux) plus intensity-modulated radiation therapy (IMRT)
Trial: 16714187
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus dipyridamole (30-325 mg daily + 200 mg twice daily)
Trial: 16714187
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (30-325 mg daily)
Trial: 16757724
Drug: Sunitinib, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib, 50 mg per day given orally for 4 consecutive weeks followed by 2 weeks off per treatment cycle.
Trial: 16764734
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving no intervention towards prescription patterns in elderly, but educational intervention for antibiotics.
Trial: 16775234
Drug: Dasatinib (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (15 to 240 mg per day) administered orally in four-week treatment cycles, once or twice daily.
Trial: 16775235
Drug: Nilotinib (AMN107)
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib (AMN107) at various doses (50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1200 mg once daily; 400 mg and 600 mg twice daily)
Trial: 16781217
Drug: Fludrocortisone 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone 0.05 to 0.2 mg
Trial: 16831964
Drug: Mitoxantrone hydrochloride,
RxNorm normalized name: MitoXANTRONE Hydrochloride, 2 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone hydrochloride, 12 mg/m2, administered monthly via intravenous infusion for 6 months followed by 3 additional treatments every 3 months
Trial: 16864730
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion after endotoxin administration
Trial: 16864730
Drug: K-channel blocker
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-channel blocker tetraethylammonium (TEA)
Trial: 16864730
Drug: NO synthase
RxNorm normalized name: nitric oxide synthase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO synthase inhibitor N(G)-monomethyl-l-arginine (L-NMMA)
Trial: 16875985
Drug: Ranolazine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (1000 mg twice a day for 6 weeks)
Trial: 16880310
Drug: Traditional diagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional diagnostic hysteroscopy with 10 mL of 3% mepivacaine hydrochloride
Trial: 16882711
Drug: 5-aza-2'-deoxycytidine (decitabine)
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aza-2'-deoxycytidine (decitabine) 15 mg/m² IV daily for 10 days + valproic acid (VPA) escalating doses orally for 10 days (maximum 50 mg/kg daily)
Trial: 16899778
Drug: Anakinra (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (1 to 2 mg per kilogram of body weight per day subcutaneously)
Trial: 16901335
Drug: Inhaled human
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled human insulin (INH, Exubera)
Trial: 16901335
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) insulin and other licensed therapies
Trial: 16925569
Drug: Single-dose rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-dose rituximab
Trial: 16952304
Drug: Anti-CCR4 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CCR4 monoclonal antibody (mAb)
Trial: 16959033
Drug: Candesartan (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (up to 32 mg/day during 6 months)
Trial: 17012043
Drug: Risk-adapted craniospinal
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-adapted craniospinal radiotherapy followed by four cycles of cyclophosphamide-based, dose-intensive chemotherapy
Trial: 17018123
Drug: Steroid-free immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-free immunosuppressive regimens
Trial: 17018123
Drug: Monotherapy for
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy for immunosuppression (12 on sirolimus)
Trial: 17018123
Drug: Campath-1H and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath-1H and sirolimus therapy
Trial: 17021321
Drug: Lenalidomide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (10 mg for 21 days every 4 weeks or daily)
Trial: 17079762
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal treatment (scaling and root planing before 21 weeks of gestation) with monthly tooth polishing and oral hygiene instruction
Trial: 17090650
Drug: Heptavalent pneumococcal
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavalent pneumococcal conjugate vaccine (7vPCV), administered in 3 consecutive doses in monthly intervals starting 6 to 9 months after alloHSCT
Trial: 17109179
Drug: Wide excision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wide excision as initial therapy
Trial: 17109179
Drug: Wide excision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wide excision as salvage therapy
Trial: 17109179
Drug: No neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No neoadjuvant or adjuvant therapy
Trial: 17116834
Drug: Imiquimod treatment
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod treatment (self-applied cream or suppositories, 3 times a week for 16 weeks)
Trial: 17130304
Drug: N(G)-Monomethyl-l-arginine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-Monomethyl-l-arginine (250 microg/kg per minute IV) during autonomic blockade
Trial: 17130304
Drug: N(G)-Monomethyl-l-arginine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-Monomethyl-l-arginine (250 microg/kg per minute IV) in intact subjects
Trial: 17133154
Drug: Levofloxacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (10 mg/kg twice a day for 10 days)
Trial: 17174643
Drug: Other evidence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other evidence-based beta blockers
Trial: 17183730
Drug: Hydralazine (182
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (182 mg for rapid-acetylators, 83 mg for slow-acetylators) and magnesium valproate (30 mg/kg) added to neoadjuvant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) every 21 days.
Trial: 17242628
Drug: Atomoxetine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (up to 1.8 mg/kg/day)
Trial: 17263626
Drug: Interferon/ribavirin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon/ribavirin therapy
Trial: 17337677
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline inhalation
Trial: 17351381
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum creatinine < 0.9 mg/dl
Trial: 17351381
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum creatinine 0.9-1.2 mg/dl
Trial: 17351381
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum creatinine 1.2-1.6 mg/dl
Trial: 17351381
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum creatinine 1.6-2.8 mg/dl
Trial: 17351381
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum creatinine >= 2.8 mg/dl
Trial: 17351381
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum creatinine (per mg/dl) in LIFE study
Trial: 17351381
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum creatinine (per mg/dl) in RENAAL study
Trial: 17351381
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum creatinine (per mg/dl) in combined studies
Trial: 17356709
Drug: 5,6-dimethylxanthenone-4-acetic acid
RxNorm normalized name: 5,6-Dimethylxanthenone-4-acetic acid
DrugBank: Vadimezan (DB06235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,6-dimethylxanthenone-4-acetic acid (DMXAA) 30 mg/kg, i.p.
Trial: 17362525
Drug: Soluble triggering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble triggering receptor expressed on myeloid cells (sTREM)-1
Trial: 17379851
Drug: Five deep
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five deep inspirations before methacholine inhalation
Trial: 17395103
Drug: Inactive antibody
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive antibody
Trial: 17425446
Drug: Pramlintide therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide therapy (120 microg)
Trial: 17426205
Drug: (18)F-FMT PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (18)F-FMT PET in combination with (18)F-FDG PET
Trial: 17426276
Drug: High-dose immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose immunosuppression followed by autologous nonmyeloablative hematopoietic stem cell transplantation (AHST)
Trial: 17426276
Drug: High-dose immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose immunosuppression followed by AHST
Trial: 17436219
Drug: Lopinavir/ritonavir (highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (highly active antiretroviral therapy)
Trial: 17450048
Drug: Adjunct services
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct services for attrition prevention (ASAP)
Trial: 17498579
Drug: BNP quartile
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP quartile Q1 (<430 pg/ml)
Trial: 17498579
Drug: BNP quartile
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP quartile Q2 (430 to 839 pg/ml)
Trial: 17498579
Drug: BNP quartile
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP quartile Q3 (840 to 1,729 pg/ml)
Trial: 17498579
Drug: BNP quartile
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP quartile Q4 (>=1,730 pg/ml)
Trial: 17502467
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (10 g daily, containing 100 mg of testosterone)
Trial: 17503986
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg/day for 6 weeks, increased to 120 mg/day for the remainder of the 12-week trial as tolerated
Trial: 17504901
Drug: Ghrelin measurement
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin measurement (hourly between 2300 and 0300 h)
Trial: 17507719
Drug: Vascular targeted
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular targeted photodynamic therapy (VTP) with palladium-bacteriopheophorbide
Trial: 17515522
Drug: Oral bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral bexarotene and extracorporeal photopheresis
Trial: 17519207
Drug: Topical autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical autologous platelet gel (APG)
Trial: 17519207
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (antibiotic ointment and/or semiocclusive dressing)
Trial: 17519207
Drug: Topical autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical autologous platelet gel (APG) with platelet count > 6 times baseline
Trial: 17536019
Drug: Sildenafil (a
RxNorm normalized name: sildenafil (as citrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (a phosphodiesterase-5 inhibitor)
Trial: 17541048
Drug: Augmentation pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation pharmacotherapy (bupropion, nortriptyline, or lithium)
Trial: 17541048
Drug: No augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No augmentation (control group)
Trial: 17541653
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 60,000 U SC QW during initial dosing phase (IDP)
Trial: 17541653
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 80,000 U SC Q3W during extended dosing phase (EDP)
Trial: 17562873
Drug: Clofarabine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofarabine (20 mg/m2) + cyclophosphamide (200 mg/m2)
Trial: 17562873
Drug: Clofarabine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofarabine (10 mg/m2) + cyclophosphamide (200 mg/m2)
Trial: 17562873
Drug: Cyclophosphamide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (200 mg/m2) alone
Trial: 17563348
Drug: Annual 4-day
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual 4-day insulin infusions and daily insulin injections
Trial: 17563856
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg once daily and docetaxel 75 mg/m(2) every 3 weeks
Trial: 17573882
Drug: Imiquimod treatment
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod treatment for AIN
Trial: 17577020
Drug: Oral vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vorinostat 400 mg daily until disease progression or intolerable toxicity
Trial: 17577020
Drug: Oral vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vorinostat 400 mg daily
Trial: 17579195
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone deficiency (GHD)
Trial: 17586030
Drug: HspE7 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HspE7 (500 microg, 3 monthly subcutaneous vaccinations)
Trial: 17586305
Drug: Low-dose AAV-GAD
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose AAV-GAD gene therapy
Trial: 17586305
Drug: Medium-dose AAV-GAD
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose AAV-GAD gene therapy
Trial: 17586305
Drug: High-dose AAV-GAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose AAV-GAD gene therapy
Trial: 17586305
Drug: AAV-GAD gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV-GAD gene therapy
Trial: 17586747
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with rosiglitazone and exercise
Trial: 17591525
Drug: Ergocalciferol 50,000
RxNorm normalized name: ergocalciferol 50,000 intl units oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergocalciferol 50,000 IU once weekly for 12 weeks and once monthly thereafter for a total of 6 months
Trial: 17591525
Drug: Ergocalciferol administration
RxNorm normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergocalciferol administration
Trial: 17596541
Drug: 5-azacitidine (5-AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5-azacitidine (5-AZA) at 75 mg/m² subcutaneously daily for 7 days, valproic acid (VPA) orally daily for 7 days (dose-escalated, maximum tolerated dose 50 mg/kg), all-trans retinoic acid (ATRA) at 45 mg/m² orally daily for 5 days starting on day 3.
Trial: 17596541
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5-AZA, VPA, and ATRA
Trial: 17597266
Drug: CJ-50300 smallpox
RxNorm normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJ-50300 smallpox vaccine
Trial: 17626713
Drug: Atorvastatin (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10, 20, 40, 80 mg/day)
Trial: 17635942
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) 1000 mg at 10- to 14-wk intervals
Trial: 17646603
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors prescribed at discharge
Trial: 17647221
Drug: Supportive-expressive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive group therapy (n = 64) with educational materials, 90 minutes once a week for a minimum of 1 year.
Trial: 17647221
Drug: Supportive-expressive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive group therapy for ER-negative participants.
Trial: 17647221
Drug: Supportive-expressive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive group therapy for ER-positive participants.
Trial: 17659962
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab injection (1.25 mg/0.05 ml)
Trial: 17666616
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor regimen
Trial: 17666616
Drug: No protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No protease inhibitor regimen
Trial: 17679729
Drug: Decitabine alone
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine alone (20 mg/m(2)/d intravenously for 10 days)
Trial: 17679729
Drug: Decitabine plus
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine plus valproic acid (VA) (at OBD, days 1 through 10, with dose-escalating VA days 5 through 21)